Frontrunner Kymera Claims Proof-Of-Concept For Protein Degrader Platform
Results From Sanofi-Partnered Asset
Kymera has unveiled the first placebo-controlled data from a protein degradation candidate, adding to heightened expectations for the novel modality.
You may also be interested in...
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.